Norprolac (Quinagolide)

Quinagolide selectively activates dopamine D2 receptors in the anterior pituitary gland. This activation inhibits adenylate cyclase, reducing the secretion of prolactin and thereby correcting the hormonal imbalance that causes the associated clinical conditions.

The dosage of Norprolac is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Only a qualified healthcare professional should determine the appropriate dose and titration schedule.

Safety data for quinagolide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Norprolac, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Norprolac (quinagolide) is a selective dopamine D2‑receptor agonist, similar in class to cabergoline and bromocriptine. Compared with bromocriptine, quinagolide often requires once‑daily dosing and may have a different side‑effect profile, while cabergoline is typically given twice weekly and is associated with a lower incidence of nausea.

Store Norprolac tablets at temperatures below 25 °C, in the original packaging, and protect them from moisture and direct sunlight. Do not store in a refrigerator or freezer unless specifically instructed by the supplier.

Norprolac is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed. It is generally taken once daily, but the exact timing and any food considerations are determined by the prescribing clinician.

Serious risks include valvular heart disease, impulse‑control disorders such as compulsive gambling, severe hypotension, and rare allergic reactions. Patients should be monitored regularly for cardiac symptoms and behavioral changes, and any concerning signs should prompt immediate medical evaluation.

Norprolac is contraindicated in patients with known hypersensitivity to quinagolide, uncontrolled hypertension, severe cardiac valve disease, or those taking ergot‑derived medications. Caution is also advised for individuals with hepatic impairment or a history of psychiatric disorders.